call review performance. a and first will mid-February. with rest the performance. business the our thoughts of some background initial my more in Thanks, you the to provide with of of results, you conclude a our since by Then CEO before overview for then like share Mike, first on of company joining since a then thanks, a will Q&A. year on financial our begin summary observations little Jared I providing color quarterly to will and of for and brief provide call the quarter everyone, the is of our joining this what doing I my my us. I'd I've as been tell CVRx, today's and I'll turning
CEO turnover. business, was which force performance led due decreased million. our XXXX. lower-than-anticipated our XX% the Heart below guidance the was million, U.S. and disruption of $XX.X our Starting at was performance over to $XX the productivity to million revenue Total of of quarter the an where with primarily during $XX to of within an overview first of The of quarter. sales our revenue organization sales some first was increase This transition, there time some the Failure
team some actions and in the that March. full will to led take the stabilizing early Failure U.S. have our returning in to performance we business productivity have encouraged I'm of While time, taken territories Heart active some solid
In fully sales made a more make discuss have I addition, later, to decision in leadership. the change as will we
of been roles began of way novel and and U.S. businesses device Medtronic Medtronic at of treatment options. most my CEO the served Europe. years, Subsequent cardiac surgery Medtronic, President medical and at I've fields. were my XX conditions mid-stage were background, been in the commercializing and around privately there which over for in in focus industry of neuromodulation I CRM, historically career limited involved the subsequently to the a novel By cardiovascular the to the years and therapies for introduction and the for high-growth these chronic has I roles globe. for therapies as Many neuromodulation Several series which and held in of both of companies. spent commercial early of there spent both in XX treatment
a I care a learned approach of of move these to systematic that and goal barriers to of of through to standard ultimate efforts of care. and addressing The therapies adoption rigorous each these specific experiences these to requires was eliminating reaching standard the them. assessment
them. are my go more that I've in for been about many I'll here into for Later, to addressing challenges only of observed months, early my and have our I familiar the and initial some Although detail of CVRx opportunities current role plans me. observations X at
XXXX. joined also operating experience, in served on and company a public my I've December which Board number private of CVRx, of of from Boards, the I Apart including
to day-to-day the me develop operations with our effectively get to a company strategy. needed to on Board business While the and the deeper and understanding I provided my long-term knowledge lead time of of market, the
understand Upon a and better and Europe commercial teams order therapy systematic of joining of with in customers review challenges to opportunities our gain tours stability listening that of and in the U.S. platform. understanding CVRx, to future opportunities I face conducted adoption Barostim company's the understand driving began leverage a and series our our of also as our well I of to to operations scalability business. as a the the we
for well-run collecting and impactful Barostim that My feedback company effective therapy my this from highly for validated heart overwhelming is are takeaway employees. patient-focused of of limited patients team a I also extremely treatment with and observation a committed highly CVRx is options remarkably failure after a wide whom is there suffering today. array that
cemented today's that surface that can treatment can in continuum heart failure the the of are patients we exists we physicians with indeed X conversations and can failure visits international scratching the heart and population for and at My my of over the fill have value in belief we field only create. that Barostim gap that XX recent the failure that congresses numerous heart help
My have we conversations physicians these me support term, HFrEF commercial in to fully in efforts near existing our that with indication. the advisers to our led believe more and need
value have strategy. our we massive mind With a be X% year's the in this highlights we we team therapy This only market now Any a in we've keeping last this market. potential alone, refine reallocation patient U.S. label billion opportunity on of annual our clinical as investment opportunity penetrated the remain the evidence, over expansion have areas $X.X and impact for Barostim, barriers adoption have coming increased on focused Barostim, existing come drive from the awareness of of HFrEF will we my the device to our for initial indication in access check. will go-to-market resources explore increased Based assessment of overall limited with in where of investment the spending I initiatives. and I and with asked quarters these working as adoption team in in competition. to of Barostim
performance below As first noted, our was quarter revenue expectations.
is critical. sales As our organization a commercial company, stage of the high-growth effectiveness
that leadership is the team in change maximize that assessment to us. in my I've of front our needed of we disruption determined on in opportunity Based a and QX, the sales saw
a result, will As Senior company. of the departing President our Vice Sales be
can search a identify a business to thorough full initiated reach We its scale to candidate who have potential. this
In place. technologies Strategy leader involved we Guidant and the Officer, and currently years with our therapies leadership experience, is as at efforts of new up sales Paul in sales medical sales our leader is Verrastro, over to head introduction Paul asked novel Chief marketing much roles and of a have Medtronic the XX interim, CRT. of Paul's the device including and Importantly, until respected ICDs Marketing senior such and experience highly
years team role our sales by been and highly actively identified. X for key goes Paul respected Paul of physician leader and new member a is but CVRx has the our It sales in saying, probably interim until organization is will customers. support his I leadership over without
In strategy. our identified my tour, therapies, Based standard experience my spent time move addition to X my priorities we've listening towards go-to-market initial and observations introducing the team near-term I've of significant care. on assessing with novel Barostim to
to through education first awareness Barostim in the among priority as The awareness is heart outreach will to continuum physician Building patients clinicians appropriate this the be and for failure. and comprehensive crucial. increase key treatment role for
the efficacy need to further evidence and the current within bolster is indication. Barostim the therapy second safety supporting clinical profile of The the
of our focus within We evidence generation post-market on are HFrEF. the increasing robust
term. limit hurdles coding, Finally, we patient as coverage with the can short in many payment, related which potential access to novel and face therapies,
these been proactively issues, While investments we will be facilitate have to we patient additional addressing making access.
bringing help believe market we in that drive to more these these actively patients address to with from out out We therapy. initiatives team reach building development To us roles areas. leadership will leaders who these build new in benefit Barostim functions priorities, are can the specifically core designed seasoned
spearhead drive care. appropriate use therapy clinicians. The awareness is integration drive The of first of Chief comprehensive will guideline education, Medical our to efforts our outreach a therapy and these towards standard of to This our CMO role guide roles and medical Officer. will among
The President current Senior development of pipeline and a studies Clinical strategy, This Vice the including Affairs. of oversee position robust and designing our within evidence optimizing indication. will the second of a generation post-market clinical execution is
quarter, in end European This data have evidence input As our development of the phase an future of plan. we results BeAT-HF post-market first announced set the the Heart you the Failure. important subsequent the of long-term of to the of be publication will trial may noticed, the Journal to
role expanding access is further Vice important President Barostim the to the third Senior Patient Lastly, of in be will Access. role therapy. This
proposal may care. recently take has inpatient a have expected The that proposed mapped Barostim made October for reimbursement through You we seen progress this code the to is paying in inpatient higher DRG XXXX. effect X, on which area to reassignment,
soon are roles X these for seeking possible. these searches fill The key as well to underway. as We're roles
the address be patient With widespread these and even adoption. leaders to to place, better in access will we evidence hurdles awareness, equipped
the highlighted product unique does groups. business core My indication our in we therapy Barostim additional commercialization on not and and mean help focus to the nature of will expansion technology pursue near-term with conversations increased patient This clinicians our the have potential not of that platform. platform optimization
and today We exists in opportunity appropriately HFrEF. the carefully future significant balance investment commercial that with this a will in
the and conducting drive be for projects review those will portfolios focus will patients. of that We to ultimately a believe both thorough clinical company our on R&D select value we our high-impact and narrow few
of in We with go-to-market R&D our XXXX. our look later updated both sharing forward and the you review portfolio findings to strategy
realization BATwire acceptable This trial. trial. safety completion. the intend not to until rather concerns, in not procedure to opposed BATwire a was physicians note, the and On to the adoption. enrolled the following candidates suggests barrier as widely elected but to commercially the the patients that to in current to many elected patient approved the related a that due we've is stop We therefore, enrollment and This to due change procedure continue in participating patients trial study
market in the optimistic improve term. tremendously already I the about execution business opportunity our near implement started and the strength in the organization. I'm to have changes Overall, our and that technology of will
we our process I'm for team leadership addition, long-term strategy look to working you when is vision In analysis the with with in which and to develop complete. our our business, sharing the forward of
call review. Jared for a like to I'd turn over Now to financial the
